Navigation Links
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Date:3/12/2008

eting and look forward to this pivotal assessment of HD-02 as a treatment for slowing Huntington's disease for which there currently is no approved treatment," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are also pleased to further strengthen our on-going relationship with Dr. Steven Hersch, Dr. Diana Rosas, and Dr. Bernard Ravina. We look forward to working with the NCCAM, a Division of NIH, and the Orphan Products Division through their sponsorship of this trial."

"We are very enthusiastic about the study results of HD-02 to date and excited to be advancing it into a Phase III trial," stated lead investigator Dr. Steven Hersch. "This Phase III study will evaluate whether HD-02 can slow the progression of Huntington's disease, and pending positive results, may provide a much needed treatment option to Huntington's patients."

ABOUT HD-02

HD-02 is a novel and proprietary drug candidate for the treatment of Huntington's disease (HD). HD-02 has been granted orphan drug designation in the U.S. Results from a Phase II clinical trial of HD-02, led by Dr. Steven Hersch of Massachusetts General Hospital, were published in the January 24, 2006 issue of Neurology and showed that HD-02 suppressed a Huntington's disease marker. Some researchers have linked this oxidative marker as a measure of cellular injury. Earlier preclinical studies performed by Dr. Flint Beal of Cornell Medical Center and Dr. Robert Ferrante of Boston University, showed that HD-02 has significant neuroprotective effects, such as improved movement, reduced neuropathology, and prolonged survival.

ABOUT HUNTINGTON'S DISEASE

Huntington's disease is a progressive neurodegenerative disease caused by a defective gene that is often inherited from parent to child. This genetic defect causes a widespread deterioration of neurons in those parts of the brain that are responsible for controlling cognitive, emotional and motor functions. This progressive deteriora
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... -- , A major pan-European survey into ... of care has revealed changing trends in many important ... provision of healthcare services across the continent. The results ... Gastroenterology (UEG), have been announced today and led to ... burden of GI disorders across Europe ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Standards and Technology (NIST) colored lots of eggs recently. ... smallin fact, too small to see without a microscope. ... strategies for making future low-power computer memories. For ... used electron-beam lithography to make thousands of nickel-iron magnets, ...
... new kind of cloaking material that can render ... this design can,t translate into an invisibility cloak ... in diagnostics, security, and communication. The cloak, ... engineering at Northwestern,s McCormick School of Engineering and ...
... 27, 2011 Talecris Biotherapeutics Holdings Corp. ("Talecris") (NASDAQ: ... for the three months ended March 31, 2011 and ... Exchange Commission (SEC). First quarter 2011 net ... million from $381.0 million in the first quarter of ...
Cached Biology Technology:Good eggs: NIST nanomagnets offer food for thought about computer memories 2Researchers create terahertz invisibility cloak 2Talecris Biotherapeutics Announces First Quarter 2011 Results 2Talecris Biotherapeutics Announces First Quarter 2011 Results 3Talecris Biotherapeutics Announces First Quarter 2011 Results 4Talecris Biotherapeutics Announces First Quarter 2011 Results 5Talecris Biotherapeutics Announces First Quarter 2011 Results 6Talecris Biotherapeutics Announces First Quarter 2011 Results 7Talecris Biotherapeutics Announces First Quarter 2011 Results 8Talecris Biotherapeutics Announces First Quarter 2011 Results 9Talecris Biotherapeutics Announces First Quarter 2011 Results 10Talecris Biotherapeutics Announces First Quarter 2011 Results 11Talecris Biotherapeutics Announces First Quarter 2011 Results 12Talecris Biotherapeutics Announces First Quarter 2011 Results 13Talecris Biotherapeutics Announces First Quarter 2011 Results 14Talecris Biotherapeutics Announces First Quarter 2011 Results 15Talecris Biotherapeutics Announces First Quarter 2011 Results 16
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... 28, 2011) University of Kentucky plant pathologists recently discovered ... the ability of plants, animals, humans and one-celled microorganisms to ... level, which is known as systemic immunity. This mode of ... the key events that stimulate that resistance have remained a ...
... Western Reserve University has detected tiny amounts of Iodine 131 ... campus building. Gerald Matisoff, professor of geology, said ... health. He estimated the level of radiation is about one-tenth ... 131 could have come from any radioactive waste processing facility," ...
... of scientists has discovered that descendants of "exploratory" butterflies ... cautious cousins. The team, led by James Marden, a ... Wheat, a post-doctoral scholar working at both Penn State ... the genetic bases for faster egg maturation, a higher ...
Cached Biology News:Kentucky researchers find a key to plant disease resistance 2Butterfly study reveals traits and genes associated with establishment of new populations 2Butterfly study reveals traits and genes associated with establishment of new populations 3Butterfly study reveals traits and genes associated with establishment of new populations 4
...
... High pH This pH 9.9 solution ... to immunohistochemical staining procedures. It is for ... on glass slides. For particular antigens, target ... effective. It should be noted that also ...
... A very potent Rnase ... effective over a broad range ... This protein does not inhibit ... polymerase, AMV and M-MLV reverse ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
Biology Products: